Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
130actual
Sites
51
Countries
Australia, Belgium, Canada +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-06-08 | actual | When the study began enrolling |
| Primary completion | 2026-04-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-17 | actual | The whole study's end, after follow-up |
| First posted | 2020-05-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Parkinson's Disease (PD)
Intervention
- Drug: ABBV-951 — also filed as Foscarbidopa, Foslevodopa
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants With Adverse Events (AE)
measured Up To Week 96
Percentage Of Participants With Numeric Grade Equal To Or Higher Than 5 On The Infusion Site Evaluation Scale
measured Up To Week 96
Percentage Of Participants With Letter Grade Equal To Or Higher Than D On The Infusion Site Evaluation Scale
measured Up To Week 96
Change in Clinical Laboratory Test Data
measured Up To Week 96
Change in Vital Signs Measurements
measured Up To Week 96
Change From Baseline in Electrocardiograms (ECGs)
measured Up To Week 96
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed